戈利木单抗治疗非放射学中轴型脊柱关节炎的疗效与安全性:撤药与再治疗研究(GO-BACK)
GO-BACK研究纳入323例活动性非放射学中轴型脊柱关节炎成人患者,经10个月开放标签戈利木单抗治疗达疾病无活动者188例,随机1:1:1分为安慰剂撤药组、戈利木单抗每月组和每2月组。继续戈利木单抗较撤药显著预防疾病复发(P<0.001),每月组与每2月组较安慰剂治疗差异分别为50.4%和34.4%。
要点
- 10个月开放标签戈利木单抗治疗后达疾病无活动者188/323例进入双盲期。
- 继续戈利木单抗每月或每2月给药均优于撤药预防复发(P<0.001)。
- 复发后重启开放标签戈利木单抗,51/53例(96.2%)3个月内达临床应答。
核心结论
- 在活动性非放射学中轴型脊柱关节炎患者中,经10个月戈利木单抗治疗达疾病无活动后,继续戈利木单抗治疗耐受性良好,且较撤药能更有效预防疾病复发。
研究设计与样本
- GO-BACK研究为撤药与再治疗研究,纳入323例成人活动性非放射学中轴型脊柱关节炎患者,第1期接受开放标签戈利木单抗治疗10个月。
- 第2期将达疾病无活动者按1:1:1随机分配至双盲安慰剂(撤药)、戈利木单抗每月或戈利木单抗每2月治疗,无复发者继续双盲治疗约12个月。
- 复发者停双盲治疗并重启开放标签戈利木单抗每月治疗,末次治疗后安全性随访约3个月。
主要发现
- 188例患者符合第2期参与条件;戈利木单抗每月组和每2月组在预防疾病复发方面均优于安慰剂撤药组(P<0.001)。
- 戈利木单抗每月组较安慰剂的治疗差异为50.4%,戈利木单抗每2月组较安慰剂的治疗差异为34.4%。
- 戈利木单抗治疗组首次复发时间较安慰剂组显著延长(对数秩检验P<0.0001)。
- 53例(每2月组或安慰剂组)确认疾病复发者中,51例(96.2%)在重启开放标签戈利木单抗每月治疗后3个月内达临床应答。
- 不良事件与戈利木单抗已知安全性特征一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in. METHODS: Eligible participants received OL GLM in period 1. In period 2, participants who achieved inactive disease were randomized 1:1:1 to receive double-blind (DB) treatment with monthly placebo (PBO, treatment withdrawal) or continued GLM treatment given monthly (GLM QMT) or every 2 months (GLM Q2MT). Participants who did not have a disease flare continued DB treatment for ∼12 months. Participants with a disease flare discontinued DB treatment and resumed monthly OL GLM. Primary endpoint compared the proportion of participants without a disease flare in the continued GLM treatment groups (QMT or Q2MT) vs PBO in a multiplicity-controlled, step-down fashion. Safety follow-up continued for ∼3 months after last treatment. RESULTS: A total of 188 patients, out of the 323 enrolled, were eligible for participation in period 2. Both GLM QMT and GLM Q2MT were superior to treatment withdrawal (PBO) in preventing disease flare (P < 0.001), with a treatment-difference vs PBO of 50.4% and 34.4% for the GLM QMT and GLM Q2MT groups, respectively. The time-to-first flare was significantly longer (log-rank P < 0.0001) with GLM treatment compared with PBO. Of 53 participants (in Q2MT or PBO) who had a confirmed disease flare, 51 (96.2%) attained a clinical response within 3 months of restarting OL GLM. Adverse events were consistent with the known GLM safety profile. CONCLUSION: Among participants with active nr-axSpA who attained inactive disease after 10 months of GLM treatment, continued GLM treatment is well tolerated and provides superior protection against disease flares compared with GLM withdrawal. (EudraCT: 2015-004020-65, registered on 30 March 2022; NCT: 03253796, registered on 18 August 2017.).
引用
- Weinstein CLJ, Sliwinska-Stanczyk P, Hála T, et al. Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK). Rheumatology (Oxford). 2023. PMID: 36919768. doi:10.1093/rheumatology/kead112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。